Time to Act – a consensus on early treatment

Publish date: 
Sep 2015

In November 2014, we facilitated a consensus meeting with key members of the MS community to consider the balance of clinical evidence and emerging practice around whether early treatment with disease modifying therapies (DMTs) improves long-term outcomes for people with MS.

It was attended by people with MS, neurologists, MS nurses, MS Society staff and MS Trust staff. This group of experts agreed that current evidence confirms the importance of treating with DMTs as close as possible to making a diagnosis of MS (consistent with people being able to make informed decisions).

This paper outlines why early treatment is important for people with relapsing forms of MS and what has led to this conclusion.

Paper published September 2015.

Page tagged with:
Page last updated: 28 Sep 2015

What's new?